-
Most Popular
Search Results
240 results for bmti
How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves
Usually, these snap decisions would have investors scrambling to play defense… But today, we’re interested in how to make our own big play. That’s because…
Bank on This Pair of Biotech Bargains
When it comes to small biotechs, one successful product can send its stock soaring. This pair of companies currently have promising treatments on the horizon.
4 Biotechnology Stocks to Buy Now
This week, four Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Bebe, Apac and JVA Stock All Reach 52-Week Highs
Stocks setting 52-week highs include Apac Customer Service NASDAQ:APAC), Bebe Stores NASDAQ:BEBE, and Coffee Holding Co NASDAQ:JVA.
7 Biotechnology Stocks to Buy Now
Seven Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an…
BioMimetic Has Suitors Lying in Wait
A key FDA OK could have the buyout offers rolling in.
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a…
Palomar Medical Technologies (PMTI) Reinventing the Fountain of Youth
Remember that song by Carly Simon, “You’re So Vain?” I heard it on the radio the other day and thought it would be good song…
BITI ETF: 10 Things to Know About the New ProShares Short Bitcoin ETF
Investors wondering how to short Bitcoin (BTC) are gaining a new option with the ProShares Short Bitcoin Strategy ETF (BITI).
Bristol-Myers Squibb Co’s (BMY) Solid Quant Score Keeps it a Buy
The current recommendation of Buy for Bristol-Myers Squibb Co (NYSE:BMY) is derived using Louis Navellier’s approach to investing and his Portfolio Grader stock evaluator. BMY…
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market’s potential. Still, patent expirations loom large and won’t be easily overcome.
Bristol-Myers Squibb Co (BMY) Industry Group Rank Penalize Rating
Bristol-Myers Squibb Co (NYSE:BMY) is a $103.5 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader’s current ranking for BMY…
Bristol-Myers Squibb Co (BMY) Ranking Raised to Buy on Superior Earnings Visibility
Bristol-Myers Squibb Co (NYSE:BMY) is a constituent of the 135 company Pharmaceuticals GICS industry group, which is part of the 783 company GICS Health Care…
Industry Group Rank Limit Bristol-Myers Squibb Co (BMY) Rating
The current recommendation of Hold for Bristol-Myers Squibb Co (NYSE:BMY) has been derived by using Louis Navellier’s methodology for investing and his Portfolio Grader stock…
Bristol-Myers Squibb Co (BMY) Earnings Growth Penalize Rating
The current recommendation of Hold for Bristol-Myers Squibb Co (NYSE:BMY) is derived using the methodology of Louis Navellier for investing and his Portfolio Grader stock…
Anemic Quant Score Restrict Bristol-Myers Squibb Co (BMY) Rating
Bristol-Myers Squibb Co (NYSE:BMY) is ranked as a Hold using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents…
1 – 10 of 240 results
